ArticleLiver cancer2025
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).
Registry-linked trialAbstract read
In one paragraph
Article in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07315022 (Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma), which is not on this map. Cited by 66 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Cohort Study
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- First-line therapies for unresectable hepatocellular carcinoma: a network meta-analysis of immune checkpoint inhibitors and transarterial therapies based on 35 randomized trials.Frontiers in oncology · 2026Pooled it
- Integrated single-cell multi-omics characterization reveals lipid-associated macrophage-mediated immunosuppression in neoadjuvant immunotherapy of hepatocellular carcinoma.Nature communications · 2026Trial
- Effect and safety of tislelizumab combined with anlotinib and radiotherapy in advanced hepatocellular carcinoma: A single-arm, single-center, phase II clinical study.Scientific reports · 2026Trial
- Association between gut microbiota characteristics and therapeutic efficacy of multimodal combination therapy in hepatocellular carcinoma with portal vein tumor thrombus: a secondary analysis of a prospective phase II trial.Frontiers in immunology · 2026Trial
- Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe.The Lancet regional health. Europe · 2026Review
- A dual-ion/immune checkpoint nanoplatform-activated pyroptosis/cGAS-STING signaling transform iMWA into systemic immunotherapy against HCC recurrence.Materials today. Bio · 2026Article
- Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab.Annals of surgical oncology · 2026Article
- Ferroptosis regulatory networks as therapeutic sensitizers in combination therapy for hepatocellular carcinoma (Review).Oncology letters · 2026Review
- Temporal Differentiation of Nonperipheral Washout Refines Prognostic Stratification in HCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Immune Checkpoint Inhibitors in Cancer Patients With Concurrent Active Tuberculosis: A Real-World Study in a High Tuberculosis Burden Region.Open forum infectious diseases · 2026Article
- Comparative efficacy of liver resectionTranslational cancer research · 2026Article
- Temperature-sensitive liquid embolic agent transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for BCLC Stage B/C hepatocellular carcinoma: a multicenter real-world study and spatial transcriptomics profiling (CHANCE 2515).Signal transduction and targeted therapy · 2026Observational
- Prognostic Value of MRI-Based Treatment Response Assessment Criteria in Hepatocellular Carcinoma After Stereotactic Body Radiotherapy: A Comparative Analysis of mRECIST, LI-RADS TRA Version 2017, and LI-RADS Radiation TRA Version 2024.Journal of magnetic resonance imaging : JMRI · 2026Article
- Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies.Biomedicines · 2026Review
- Potentially Functional Variants ofCancers · 2026Article
- Prognostic and therapeutic significance of microscopic tumor focus in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study.Journal of gastrointestinal oncology · 2026Article
- Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study.BMC medicine · 2026Article
- Machine learning-driven evaluation of protein kinase D3 as a co-diagnostic biomarker in hepatocellular carcinoma.Journal of Zhejiang University. Science. B · 2026Article
- Article
- Pharmacokinetics and anti-tumor efficacy of transarterial chemoembolization using small-particle lenvatinib-loaded beads in a rabbit VX2 liver tumor model.Quantitative imaging in medicine and surgery · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
124 authors.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Huichuan SunLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenming CongDepartment of Pathology, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Weiping ZhouDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Lianxin LiuDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Tianfu WenDepartment of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Ming KuangCenter of Hepato-Pancreate-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Bixiang ZhangHepatic Surgery Center, Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Kaishan TaoDepartment of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Guohong HanDepartment of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Maoqiang WangDepartment of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Ruibao LiuDepartment of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China.
Jinhe GuoDepartment of Interventional and Vascular Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Zhaochong ZengDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ping LiangDepartment of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Zhenggang RenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jinlin HouDepartment of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Xiufeng LiuDepartment of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Hongming PanDepartment of Medical Oncology, Sir Run-Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Feng BiDepartment of Abdominal Tumors, West China Hospital, Sichuan University, Chengdu, China.
Changhong LiangDepartment of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Min ChenDepartment of Radiology, Beijing Hospital, Peking University, Beijing, China.
Fuhua YanDepartment of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Huixiong XuDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaoyan XieDepartment of Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Shenghong JuDepartment of Radiology, Zhongda Hospital, Southeast University, Nanjing, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingping YunDepartment of Pathology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.
Zengshan LiDepartment of Pathology, Xijing Hospital and School of Basic Medicine, Xi'an, China.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Dingfang CaiDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Weixia ChenDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Yajin ChenDepartment of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Yongjun ChenDepartment of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenwu ChengDepartment of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuqun ChengDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Zhi DaiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Chaoliu DaiDepartment of Hepatobiliary and Spleeny Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Qiang GaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongping GuoDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Wengzhi GuoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yabing GuoDepartment of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Baojin HuaGraduate School, Beijing University of Chinese Medicine, Beijing, China.
Xiaowu HuangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Hanyu JiangDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Weidong JiaDepartment of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Qiu LiDepartment of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Tao LiDepartment of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
Xiangcheng LiDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xun LiDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China.
Yaming LiDepartment of Nuclear Medicine, the First Hospital of China Medical University, Shenyang, China.
Yexiong LiDepartment of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Oncology, Peking University International Hospital, Beijing, China.
Xiao LiangKey Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Changquan LingOncology Department of Traditional Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Hui LiuDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shichun LuInstitute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China.
Guoyue LvDepartment of General Surgery, the First Hospital of Jilin University, Changchun, China.
Yilei MaoDepartment of Hepatic Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Zhiqiang MengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Tao PengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Weixin RenDepartment of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Guoming ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Hongcheng ShiDepartment of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Ming ShiDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Tianqiang SongDepartment of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Guang TanDepartment of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jianhua WangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kui WangDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Lu WangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Wentao WangDepartment of Liver Surgery and Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.
Xiaoying WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiming WangDepartment of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Jun XiaGRADE Center, The University of Nottingham Ningbo, Ningbo, China.
Baocai XingDepartment of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Jianming XuDepartment of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Jun XuDepartment of Surgery, The First Hospital of Shanxi Medical University, Taiyuan, China.
Jianyong YangDepartment of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Xinrong YangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yefa YangDepartment of Hepatic Surgery and Interventional Radiology, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yunke YangDepartment of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaohong YaoInstitute of Pathology and Southwest Cancer Center, Third Military Medical University (Army Medical University), Chongqing, China.
Zhenyu YinDepartment of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China.
Zhengang YuanDepartment of Oncology, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Yongyi ZengDepartment of Hepatobiliary Surgery, Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Yong ZengCenter of Hepato-Pancreate-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Boheng ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Leida ZhangDepartment of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Shuijun ZhangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ti ZhangDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhiwei ZhangHepatic Surgery Centre at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ming ZhaoMinimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Yongfu ZhaoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Honggang ZhengDepartment of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Ledu ZhouDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Jiye ZhuDepartment of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
Kangshun ZhuDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yinghong ShiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Rong LiuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Lan ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yongsheng XiaoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Chun YangDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhifeng WuDepartment of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhengbin DingLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaodong ZhuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng TangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaoyong HuangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Hong HanDepartment of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Hong WuDepartment of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Minshan ChenDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Weilin WangKey Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qiang LiDepartment of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jianqiang CaiDepartment of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Feng ShenDepartment of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Xiujun CaiKey Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shukui QinNanjing Tianyinshan Hospital, China Pharmaceutical University, Nanjing, China.
Gaojun TengCenter of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), which accounts for approximately 75-85% of primary liver cancers, ranks 4th in newly diagnosed cases among various types of cancer in China, and is the 2nd leading cause of cancer-related mortality, thereby posing a significant threat to the life and health of the Chinese population. Since the publication of the "
Indexed as
ChinaDiagnosisGuidelinesHepatocellular carcinomaTreatment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
NCT07315022ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.